Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 5/20 | 0.57 |
| ▸ | LYN | P07948 | 4/20 | 0.57 |
| ▸ | TXK | P42681 | 1/20 | 0.57 |
| ▸ | CDK2 | P24941 | 10/20 | 0.56 |
| ▸ | CDK1 | P06493 | 10/20 | 0.56 |
| ▸ | CCNT1 | O60563 | 7/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 7/20 | 0.56 |
| ▸ | CDK9 | P50750 | 7/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.56 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.56 |
| ▸ | FLT3 | P36888 | 2/20 | 0.56 |
| ▸ | CCND3 | P30281 | 1/20 | 0.56 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.56 |
| ▸ | JAK3 | P52333 | 5/20 | 0.54 |
| ▸ | EGFR | P00533 | 4/20 | 0.54 |
| ▸ | AURKA | O14965 | 4/20 | 0.54 |
| ▸ | DCLK1 | O15075 | 4/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1631544 | 0.86 | CDK1 (0.51) | SYKCDK2CDK1CCNT1CCNB1 | |
| SCHEMBL1633112 | 0.83 | BRD4 (0.56) | SYKLYNCDK2CDK1CCNT1 | |
| SCHEMBL1632161 | 0.81 | CDK1 (0.59) | SYKLYNTXKCDK2CDK1 | |
| SCHEMBL1633611 | 0.78 | SYK (0.54) | SYKLYNCDK2CDK1CCNT1 | |
| SCHEMBL3996126 | 0.77 | AURKA (0.67) | SYKLYNCDK2CDK1CCNT1 | |
| SCHEMBL1571457 | 0.77 | CDK1 (0.51) | SYKCDK2CDK1CCNT1CCNB1 | |
| SCHEMBL1865341 | 0.76 | CDK2 (0.53) | SYKLYNCDK2CDK1CCNT1 | |
| SCHEMBL2438258 | 0.76 | CDK1 (0.53) | SYKLYNCDK2CDK1CCNT1 | |
| SCHEMBL11294980 | 0.75 | CDK2 (0.52) | SYKLYNCDK2CDK1CCNT1 | |
| SCHEMBL3016793 | 0.75 | CDK1 (0.57) | SYKLYNCDK2CDK1CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| EP-2004615-A2 | QUINAZOLINES FOR PDK1 INHIBITION | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007117607-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007117607-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | SYK 4204/4885LYN 1544/4885TXK 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.